GlaxoSmithKline Invests 500 Million Euros (US $635M) In French Vaccine Plant

September 29, 2006 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

LONDON, Sept 29 (Reuters) - Europe's biggest drugmaker, GlaxoSmithKline Plc (GSK.L: Quote, Profile, Research), is to invest more than 500 million euros ($636 million) at a new production plant in France to expand vaccine manufacturing capacity.

>>> Discuss This Story

Twitter
LinkedIn
Facebook
Email
Print

Real estate Europe

GlaxoSmithKline